MONTREAL--(BUSINESS WIRE)--Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that it will be participating in a panel session on the discovery and development of breakthrough treatments utilizing innovative chemistry approaches and technologies, taking place on May 5 at the 2010 BIO International Convention in Chicago.
